Global infectious disease (treatment, vaccines and diagnostics) markets expected to reach $ 106.3 billion by 2026 –



DUBLIN – (COMMERCIAL THREAD) – “Global Infectious Disease Treatment Markets” report has been added to offer.

The global infectious disease (treatment, vaccines and diagnostics) market in 2021, was valued at $ 72 billion and is expected to reach $ 106.3 billion by 2026, at a compound annual growth rate (CAGR) of 8% during the forecast period of 2021-2026.

The Americas are the largest market, followed by Europe, throughout the forecast period. The higher cost of treatment explains the higher market values ​​in these two markets, although the number of cases may be lower than in other parts of the world. Other markets are also growing, which can be attributed to an increasing prevalence and increased awareness associated with WHO interventions.

Among vaccines, influenza vaccines have the highest market value in the market, with growth over the next few years driven by conversion to quadrivalent vaccines and vaccination of the elderly population. The influenza market is also heavily influenced by the COVID-19 pandemic, due to which sales have increased. Government intervention led to an increase in vaccination during the 2020 pandemic period and thus contributed to market income. In terms of growth, Zika and Dengue vaccines have high growth potential. The markets for vaccines against diseases such as viral hemorrhagic fevers depend on the severity and occurrence of the next outbreak and the decision of health authorities to integrate vaccination against the disease into their national programs. The respiratory syncytial virus vaccine market is also expected to grow at a high CAGR due to the planned launch of Nirsevimab by AstraZeneca / Sanofi in 2023.

For diagnostics, HIV / AIDS, tuberculosis, malaria and hepatitis C are some of the high value added markets, due to the high disease burden as well as the need for a clinically confirmed diagnosis. RSV, herpes, and influenza test kits are underutilized in developing economies because the clinician can diagnose them, based on clinical findings, with some precision. Thus, unless the cost of diagnostic kits is lowered, diagnosis of the disease will be a combination of observation of symptoms by a clinician and recommendation of a diagnostic test. Resistance to current therapeutic standards is a major problem and newer detection kits also include tests to identify it.

The report includes

  • An updated review of the global infectious disease treatment markets in the pharmaceutical and healthcare industry

  • Global market trend analyzes, with data from 2019-2020, estimates for 2021 and CAGR projections to 2026

  • Assessing and forecasting the overall market size in terms of dollar value, and analyzing the corresponding market share by disease type and geographic region

  • Highlights of the market potential for Infectious Disease Treatments, opportunities and gaps estimating current and future demand; and impact of COVID-19 on the growth of this market

  • Focus on new drugs and innovations in chemicals, vaccines, biologics and diagnostic kits, recently launched or under development

  • Discussion of growing concerns about antibiotic resistant organisms and their sometimes fatal effects on humans

  • Technological assessment of the current state of infectious diseases globally, disaggregated by disease type (i.e. bacterial, viral, parasitic and fungal) and appropriate, current and planned treatments

  • Overview of the competitive landscape with key mergers and acquisitions (M&A), collaborative arrangements, and company revenue share analysis in the global infectious disease market

  • Review of the main patents granted and new technologies related to innovations in the treatment of infectious diseases

  • Company profiles of major industry players including Abbott, AbbVie, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Novartis and Roche

Main topics covered:

Overview of the disease

Market dynamics

Impact of COVID-19

Markets and forecasts

  • Global Infectious Disease Treatment Market By Region

  • Global Infectious Disease Therapy Market By Disease Type

  • Global Infectious Disease Vaccines Market By Disease Type

  • Global Infectious Disease Diagnostics Market By Disease Type

  • Global infectious diseases

  • Hepatitis B and Hepatitis C

  • Herpes simplex virus

  • HIV / AIDS

  • Influenza A and B

  • Rotavirus

  • Respiratory syncytial virus

  • Malaria

  • Tuberculosis

  • MERS-CoV

  • Viral hemorrhagic fevers

Antibiotic resistance

Research and development

Next-generation predictive tools

  • Why do we need forecasting tools?

  • Infectious Disease Modeling Tools

  • Mobile applications in infectious disease modeling

  • Current limitations of infectious disease modeling

Patent analysis

Competitive landscape

  • Mergers and acquisitions and collaborations

  • Market share of infectious disease market

  • Hepatitis B and Hepatitis C Market

  • Market share of therapeutic products against HIV / AIDS

  • Influenza vaccine market shares

  • Rotavirus vaccine market shares

Company Profiles

  • Abbott

  • Abbvie inc.

  • Astrazeneca Pharmaceuticals

  • Bristol-Myers Squibb Co.

  • SPA Diasorin

  • Gilead Sciences Inc.

  • Glaxosmithkline

  • Johnson & johnson

  • Merck & Co, Inc.

  • Novartis AG

  • Orasure Technologies Inc.

  • rock

  • Sanofi SA

  • Seqirus, A Csl Co.

  • Siemens Healthineers

For more information on this report, visit

About is the world’s leading source for market research reports and international market data. We provide you with the latest data on international and regional markets, key industries, major companies, new products and the latest trends.



Comments are closed.